Novel Neurochemical Pathways in the Pathogenesis of Developmental Epileptic Encephalopathies

Sunday, December 5, 2021
-

You may need to log in to view video on this page.

OVERVIEW:

This symposium will highlight 3 developmental epileptic encephalopathies (DEEs), focusing on phenotypic manifestation and approaches to diagnosis and management of patients: tuberous sclerosis complex (TSC), PCDH19 epilepsy, and CDKL5 deficiency disorder (CDD). They are all rare, refractory epilepsies, with unique clinical presentations, neurodevelopmental comorbidities, significant treatment challenges, and considerable humanistic burden. Faculty will discuss current and emerging approaches to the treatment of these conditions in the context of the rapidly advancing landscape of disease-specific therapies.

Sponsor: Zogenix, Inc. 

Learning Objectives:

Following participation in this activity, learners will be able to:

  • Discuss the role of the serotonergic pathway in epilepsy, neurodevelopment, and SUDEP 
  • Discuss the differentiating properties of Sigma-1 and its proposed novel role in epilepsy 
  • Appraise clinical approaches to the selection of ASMs based on mechanism of action and the role of rational polypharmacy

Education Credit:

CME provided by Miller Medical Communications, LLC

Activity Type
Satellite Symposia
Credit
CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Scientists/Researchers
Advanced Practice Providers
Advocates
Pharmacists
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals